Thread: New Research- Long term use of MAO-B inhibitors may slow Parkinson's progression
View Single Post
Old 03-08-2017, 03:08 AM
johnt johnt is offline
Senior Member
  
Join Date: Apr 2009
Location: Stafford, UK
Posts: 1,059
15 yr Member
johnt johnt is offline
Senior Member
 
Join Date: Apr 2009
Location: Stafford, UK
Posts: 1,059
15 yr Member
Default
Unfortunately, the paper on which this report is based [1] is behind a paywall. But, Medicalxpress are reporting [2]:

"A one year increase in duration of MAO-B inhibitor exposure was associated with a benefit equivalent in magnitude to approximately 20% of the annual decline in Activities of Daily Living, Ambulatory Capacity, and Global Disability observed in participants not receiving an MAO-B inhibitor."

References:

[1] "Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson’s Disease: An Analysis of NET-PD LS1"
Hauser Robert, et al.
Journal of Parkinson's Disease, 2017
Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson’s Disease: An Analysis of NET-PD LS1 - IOS Press

[2] Extended use of MAO-B inhibitors slows decline in Parkinson's disease patients

John
__________________
Born 1955. Diagnosed PD 2005.
Meds 2010-Nov 2016: Stalevo(75 mg) x 4, ropinirole xl 16 mg, rasagiline 1 mg
Current meds: Stalevo(75 mg) x 5, ropinirole xl 8 mg, rasagiline 1 mg
johnt is offline   Reply With QuoteReply With Quote
"Thanks for this!" says:
jeffreyn (03-08-2017)